导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 11.28% | 87/354 |
| 近一周 | -1.45% | 125/356 |
| 近一月 | -3.22% | 196/362 |
| 近一季 | -1.93% | 179/362 |
| 近半年 | 17.46% | 48/358 |
| 近一年 | 15.00% | 92/349 |
| 近两年 | 40.49% | 101/314 |
| 近三年 | 74.29% | 36/244 |
| 成立以来 | 1079.20% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.58% 235/360 |
25.58% 34/366 |
- - |
- - |
| 2025 | 16.11% 211/358 |
-8.73% 294/340 |
16.92% 37/348 |
7.70% 196/354 |
1.03% 126/358 |
| 2024 | 25.86% 39/329 |
8.60% 56/280 |
7.90% 60/310 |
0.25% 237/318 |
7.14% 29/329 |
| 2023 | 56.33% 2/275 |
18.81% 18/205 |
20.92% 7/230 |
-3.63% 84/262 |
12.92% 40/276 |
| 2022 | -28.14% 134/201 |
-9.40% 83/153 |
-18.36% 133/164 |
-0.13% 39/189 |
-2.72% 179/202 |
| 2021 | 22.99% 33/150 |
2.06% 136/312 |
9.23% 73/328 |
1.18% 42/358 |
9.03% 38/151 |
| 2020 | 36.97% 15/103 |
-9.87% 121/280 |
29.80% 34/295 |
8.16% 64/299 |
8.24% 148/305 |
| 2019 | 39.95% 3/88 |
14.17% 59/258 |
6.18% 16/268 |
3.85% 43/253 |
11.17% 47/266 |
| 2018 | 2.91% 12/79 |
- - |
- - |
- - |
-17.11% 190/241 |
| 2017 | 23.94% 19/69 |
- - |
- - |
- - |
- - |
| 2016 | 12.79% 12/59 |
- - |
- - |
- - |
- - |
| 2015 | 17.03% 2/49 |
- - |
- - |
- - |
- - |
| 2014 | 17.36% 6/99 |
- - |
- - |
- - |
- - |
| 2013 | 29.37% 5/70 |
- - |
- - |
- - |
- - |
| 2012 | 15.14% 15/51 |
- - |
- - |
- - |
- - |
| 2011 | -3.10% 1/27 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 广发中证香港创新药ETF(QDII) | 1.2744 | 27.49% |
| 广发道琼斯石油指数人民币A | 3.2498 | 26.68% |
| 广发道琼斯石油指数人民币C | 3.1927 | 26.58% |
| 广发道琼斯石油指数(QDII-LOF)人民币E | 3.2003 | 26.55% |
| 广发中证香港创新药ETF发起式联接(QDII)C | 1.3286 | 26.01% |
| 富国标普石油天然气勘探及生产精选行业ETF(QDII) | 1.4105 | 25.68% |
| 汇添富恒生生物科技ETF(QDII) | 1.1055 | 25.31% |
| 南方恒生生物科技ETF(QDII) | 1.1206 | 25.14% |
| 华宝标普油气上游股票美元A | 0.1538 | 24.94% |
| 广发中证香港创新药ETF发起式联接(QDII)A | 1.3401 | 24.24% |
| 国泰纳斯达克100指数 VS. 建信富时100指数(QDII)人民币A(539003) |